Tumor Targeting
Tumor Targeting - Related Videos
12:42
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
0 Views •
Cited by 17 •
2019
This protocol describes a detailed workflow for the generation and ex vivo characterization of oncolytic viruses for expression of immunomodulators, using measles viruses encoding bispecific T cell engagers as an example. Application and adaptation to other vector platforms and transgenes will accelerate the development of novel immunovirotherapeutics for clinical translation.
03:36
Pretargeted Radioimmunotherapy: A Method for Targeted Delivery of Therapeutic Radionuclides to Tumors
0 Views •
2023
This video describes the technique of pretargeted radioimmunotherapy or PRIT, in which immunoconjugates followed by radioligands are administered for treating tumors. This radioimmunotherapy reduces radiation doses to healthy tissues and utilizes radionuclides with very low half-lives incompatible with antibody-based vectors.
11:52
Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors
0 Views •
Cited by 1 •
2013
This article details the procedures for optical imaging analysis of the tumor-targeted nanoparticle, HerDox. In particular, detailed use of the multimode imaging device for detecting tumor targeting and assessing tumor penetration is described here.
10:13
A Brain Tumor/Organotypic Slice Co-culture System for Studying Tumor Microenvironment and Targeted Drug Therapies
0 Views •
Cited by 29 •
2015
Many types of human brain tumors are localized to specific regions within the brain and are difficult to grow in culture. This protocol addresses the role of tumor microenvironment and investigates new drug treatments by analyzing fluorescent primary brain tumor cells growing in an organotypic mouse brain slice.
08:11
Measuring Growth and Gene Expression Dynamics of Tumor-Targeted S. Typhimurium Bacteria
0 Views •
Cited by 22 •
2013
The goal of these experiments is to generate quantitative time-course data on the growth and gene expression dynamics of attenuated S. typhimurium bacterial colonies growing inside tumors. This video covers tumor cell preparation and implantation, bacteria preparation and injection, whole-animal luminescence imaging, tumor excision, and bacterial colony counting.
FAQs
Tumor-associated molecular markers provide distinguishing features that researchers can use to direct diagnostic or therapeutic agents toward malignant tissue. Their value depends on how reliably they identify tumor cells relative to healthy cells and how consistently they occur across a tumor. Because tumors can be heterogeneous, marker-based strategies also help researchers examine differences in targeting among tumor regions or patients.
Ligand-receptor binding directs an agent through a specific interaction between a ligand and its matching receptor, whereas antibody recognition uses antibody binding to identify a molecular feature. Both mechanisms can support selective delivery or imaging, but they depend on the presence and accessibility of their respective targets. Comparing them helps researchers select an approach suited to the biological characteristics of a tumor.
Altered tumor vasculature can influence how diagnostic or therapeutic agents reach and accumulate in tumor tissue, while locally responsive release systems are designed to act near malignant cells. These mechanisms address distribution rather than recognition alone. Their performance is shaped by biological barriers that may limit access, making delivery patterns important when interpreting targeting efficiency and potential effects on healthy tissue.
Cancer researchers apply targeting strategies to targeted drug delivery, molecular imaging, radiotherapy, and immunotherapy. In drug delivery, targeting seeks to concentrate an agent near malignant cells; in imaging, it supports preferential visualization of tumor tissue. Radiotherapy and immunotherapy likewise use targeting principles to direct activity toward cancer-related sites, with the broader goal of improving selectivity and reducing systemic toxicity.
Assessment focuses on whether a strategy recognizes, accumulates in, or acts preferentially on tumor tissue while limiting effects on healthy cells. Researchers can interpret targeting through the strategy's molecular recognition, tissue distribution, or local activity, depending on whether it supports imaging, drug delivery, radiotherapy, or immunotherapy. Such evaluation also reveals how biological barriers influence therapeutic distribution.
Tumor heterogeneity means that relevant molecular markers, receptors, or tissue features may not be uniform throughout a malignancy. Consequently, a strategy may perform differently across tumor regions, while treatment resistance can alter expected therapeutic effects. Studying both factors helps cancer researchers understand why targeting outcomes vary and refine approaches intended to maintain activity against malignant tissue without increasing effects on healthy cells.